阿托伐他汀对急性冠脉综合征患者hsCRP、IL-6、TNF-α水平的影响

摘要

大量研究证实炎症反应在急性冠脉综合征(ACS)的发生、发展及预后中起着决定性作用.阿托伐他汀具有许多独立于调脂以外的其他作用,其中以抗炎作用最为明显.研究表明阿托伐他汀能降低ACS患者超敏C反应蛋白(hsCRP)、白介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)等炎性因子水平,进而抑制术后炎症反应,改善术后血流灌注,减少急性冠脉事件的发生.本文就阿托伐他汀对ACS患者hsCRP、IL-6、TNF-α水平的影响作一综述.%Many researches proved that inflammation plays a decisive role in occurrence, development and prognosis of acute coronary syndrome (ACS).Atorvastatin possesses many other effects besides lipid regulation, and anti-inflammatory effect is the most significant one.Some studies indicated that atorvastatin can reduce levels of high sensitive C reactive protein (hsCRP), interleukin (IL)-6 and tumor necrosis factor (TNF)-α in ACS patients, then inhibit postoperative inflammation, improve postoperative blood flow perfusion and reduce occurrence of acute coronary events.The present article made a review on influence of atorvastatin on levels of hsCRP, IL-6 and TNF-α in ACS patients.